FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.
What happened
FDA inspected LGM Pharma Solutions' Irvine, CA drug manufacturing facility from May 11 to May 18, 2026. FDA found inadequate investigations of out-of-specification (OOS) assay results and inadequate process validation, including a failed process performance qualification batch and OOS stability results for tablets. FDA reviewed the firm's June 9, 2026 response and found it inadequate; the letter also notes a commercial batch was recalled and that the firm stopped making the affected drug products.
What FDA found
LGM did not thoroughly investigate unexplained out-of-specification (OOS) assay results for multiple stability and commercial batches, did not identify true root causes, and did not implement effective corrective and preventive actions (CAPA).
21 CFR 211.192LGM delayed appropriate market action after a confirmed OOS assay result and kept the investigation open without scientific justification.
21 CFR 211.192LGM failed to adequately validate the manufacturing process for its tablets; a process performance qualification batch failed an active-ingredient specification, but the validation report was approved without adequate justification.
21 CFR 211.100(a)LGM did not adequately assess in-process critical quality attributes for tablets, including particle size distribution and tablet thickness, and did not set appropriate specifications.
21 CFR 211.100(a)
What FDA wants
FDA asks LGM to respond within 15 business days with independent lab and OOS reviews, a CAPA and process-validation remediation plan, and a risk assessment for affected tablets still within expiry; FDA also recommends a qualified CGMP consultant and says LGM must notify FDA before resuming manufacturing.
Who should pay attention
- brands that buy finished tablets from LGM
- distributors or pharmacies holding LGM-made tablets still in expiry
- quality teams responsible for OOS investigations and process validation
This is a summary. Read the original letter on fda.gov.